Tacrosolv – a novel Marinosolv enabled solution

  • Tacrosolv – a novel Marinosolv enabled solution 1
  • Tacrosolv – a novel Marinosolv enabled solution 2
Product Description

Marinosolv technology significantly extends ocular tissue penetration, enabling a faster onset of efficacy due to high bioavailability of active pharmaceutical ingredients, while enhancing tolerability and safety through a substantial reduction in dosage and minimized systemic exposure.

Read more Show less

Marinomed Biotech AG

  • Country/Region:
    Austria
  • On CPHI since:
    2020
  • Employees:
    25 - 49
Company types
Biopharmaceutical company
Manufacturer/Innovator
Pharmaceutical company
Primary activities
Biopharmaceutical
Contract Research Organisation
Laboratory Services
Medical Devices
Pharmaceutical Company (innovator finished products)
View company profile
Categories
more categories Show less
Specifications
  • Details
    Tacrolimus - a highly active immunosuppressant

    For treatment of inflammatory diseases of the anterior segment of the eye (eg. moderate to severe dry eye disease, atopic allergic keratoconjunctivitis, non-infectious anterior uveitis, herpetic stromal keratitis and others).

    Marinosolv® enables Tacrolimus to achieve its full therapeutic potential even at very low concentrations. Tacrosolv is a patented, preservative-free ophthalmic prescription solution.

  • Selling Points
    Tacrosolv is an investigational medicinal product to treat inflammatory diseases of the anterior segment of the eye, representing a novel a treatment option for ocular allergy, dry eye disease in patients not responding to tear substitutes.

    Development status: Phase II results published

    Based on the novel Marinosolv® enabled formulation it will be the the first and only tacrolimus-based solution in the topical anti-inflammatory field. 

    Currently, we are actively seeking strategic partners for local and regional licensing and commercialization.

  • Model
    eye drops
More specifications Fewer specifications
Sales Markets
Show more Show less

Marinomed Biotech AG

  • Country/Region:
    Austria
  • On CPHI since:
    2020
  • Employees:
    25 - 49
Company types
Biopharmaceutical company
Manufacturer/Innovator
Pharmaceutical company
Primary activities
Biopharmaceutical
Contract Research Organisation
Laboratory Services
Medical Devices
Pharmaceutical Company (innovator finished products)
View company profile

More Products from Marinomed Biotech AG (2)

  • Budesolv

    Product Budesolv

    Marinosolv® – The Enabling Technology Behind BudesolvBudesolv is an innovative aqueous budesonide formulation based on Marinosolv® drug delivery platform, which has the potential to dramatically improve the solubility and bioavailability of poorly water-soluble compounds. This leads to faster therapeu...
  • Solv4U

    Product Solv4U

    Marinosolv® enables a strongly increased solubilization and thereby enhanced bioavailability of hydrophobic small molecules and peptides. Consequently, more efficient treatments of a multitude of diseases can be envisaged. Marinosolv® technology facilitates targeted drug delivery with a low systemic off-ta...

Marinomed Biotech AG resources (1)